Subscribe
Michele Rhee: Thyroid Cancer, a Benign Heart Tumor, and Traversing All Seven Continents

Out of Patients with Matthew Zachary

Michele Rhee: Thyroid Cancer, a Benign Heart Tumor, and Traversing All Seven Continents

December 1, 2020
ADVERTISEMENT

Michele Rhee: Thyroid Cancer, a Benign Heart Tumor, and Traversing All Seven Continents

On the show today, I welcome Michelle Rhee, young adult cancer survivor of Thyroid Cancer (you know, “the good one” I’M KIDDING) whose ordeal left her having over a dozen major surgeries, including open heart surgery for a related underlying rare disease. Back in the heyday when the young adult cancer movement was taking off, Michele was looking to take an active role in our startup culture. After being introduced, I helped land her an internship at the Children’s Cause for Cancer Advocacy, a landmark organization that everyone should know about, which helped launch my career in founding Stupid Cancer. She received BOTH her MBA and MPH in three years and, because she’s such an underachiever, went on to pursue a storied career thus far representing the voice of the patient at every company she’s worked for; including The National Brain Tumor Society, Takeda Oncology, Bluebird Bio, and now as the VP of Patient Affairs at X4 Pharma. She’s also traversed ALL SEVEN continents in a quest to find herself, make sense of the madness, and live her life on her terms. So, prepare yourself for an inspirational conversation amongst friends, and if my “conversation amongst friends” I mean “eavesdropping on our first phone call in 7 years,” well, then you’re in for a treat. Learn more about the Children’s Cause for Cancer Advocacy

ADVERTISEMENT
TransferWise

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Proudly supported by:

cover
Hera Diagnostics is eradicating cervical cancer in developing communities Teo Tijerina is the CEO of Hera Medical Devices, a cancer diagnostics startup currently focusing on bringing a cervical cancer screening tool to market.